The patients from this subgroup may benefit from immune checkpoint inhibitors, similarly to pediatric patients with glioblastoma in the context of MMR deficiency [29,30], while patients from G3/NF1 and G4/RAF subgroups may respond to targeted therapy with RAF and MEK inhibitors [31] (Figure 6). This evidence concerns the gene NF1 and mismatch repair cancer syndrome 1.